One of the most significant advancements in treating cancer has been the advent of immune-based therapies that harness the body’s immune system to fight cancer. 

This focus has led Janssen Oncology to form a dedicated, multi-functional team entirely focused on immuno-oncology research.  This approach includes chimeric antigen receptor-T cell (CAR-T) therapy, T cell redirection, vaccines and more. 

A Novel Oncolytic Virus Platform

The acquisition of BeneVir Biopharma, Inc., a biotechnology company in Maryland, offers a potential best-in-class technology, T-Stealth™ Oncolytic Virus Platform, which tailors oncolytic viruses to avoid destruction by the body’s immune system. 

These engineered viruses are intended to infect and directly destroy cancer cells, mobilize the immune system to hunt down and destroy solid tumor cells throughout the body, and enhance the effectiveness of other immunotherapies.